13F Holdings
中文EN

LTRN Lantern Pharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1763950 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.1%
TTM EPS YoY8.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-400.9%
ROA-143.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets137.4%
Debt / equity—
Current ratio1.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-35.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$11.51M$16.13M$11.89M$8.60M$7.57M
SG&A expense$6.46M$6.09M$5.98M$5.83M$5.02M
Operating income-$17.98M-$22.22M-$17.88M-$14.43M-$12.59M
Pretax income$16.98M————
Net income-$17.12M-$20.78M-$15.96M-$14.26M-$12.36M
EBITDA-$17.96M-$22.20M-$17.86M-$14.42M-$12.58M
EPS (basic)-1.57-1.93-1.47-1.31-1.13
EPS (diluted)-1.57-1.93-1.47-1.31-1.13
Weighted avg. shares (diluted)10.90M10.76M10.84M10.85M10.90M
Balance sheet
Cash & equivalents$4.42M$7.51M$21.94M$37.20M$51.52M
Short-term investments$5.70M$16.50M$19.36M$17.99M$19.20M
Current assets$10.80M$25.25M$43.34M$58.72M$72.72M
PP&E, net$31,875$47,440$52,127$48,008$30,245
Total assets$11.04M$25.57M$43.65M$58.84M$73.95M
Current liabilities$4.50M$4.33M$2.68M$2.80M$2.33M
Total liabilities$4.50M$4.38M$2.74M$2.80M$2.38M
Shareholders' equity$6.53M$21.19M$40.91M$56.04M$71.57M
Shares outstanding11.25M10.78M10.72M10.86M11.09M
Cash flow statement
Operating cash flow-$15.68M-$17.81M-$14.35M-$12.77M-$10.59M
Capital expenditure$1,715$12,595$18,734$27,844$15,499
Free cash flow-$15.68M-$17.83M-$14.37M-$12.80M-$10.61M
Investing cash flow$11.06M$3.37M-$930,210$179,268-$19.53M
Financing cash flow$1.50M$66,710-$499,997-$2.18M$63.42M
Depreciation & amortization$17,280$17,282$14,615$10,081$6,761
Stock-based compensation$651,000$652,000$1.02M$1.19M$961,545
Share buybacks——$499,997$2.48M$939,666

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.